Phase 1 Study of SYT-510 to Assess Bioavailability and Safety in Healthy Participants
A Phase 1 study is underway to evaluate the bioavailability and safety of SYT-510 in healthy participants.
Therapeutic Area
Therapeutic area intelligence for Oral formulation with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.